Rs 410/Share Dividend Approved: 114-Yrs Old Pharma Giant Declares 24% Growth In Net

Leading pharmaceuticals company Abbott India Ltd on May 9 declared a jump of 24% year-on-year (YoY) in net profit to Rs 287 crore for Q4 of FY2023-24. Its revenue soared 7% to Rs 1439 crore as against Rs 1343 crore reported in the year-ago period, as per the BSE filing. The Board of Directors of Abbott India Ltd recommended a final dividend of Rs 410/- per equity share of Rs 10/- each for year ended March 31, 2024. Last trading price of Abbott India share on BSE is Rs 25,557.05 per share with intraday fall of 1.50%. More details below:

Abbott India Ltd Recommends Final Dividend: As per the BSE filing of Abbott India dated May 9, "the Board of Directors at its Meeting held today i.e., May 9, 2024, recommended payment of final dividend of Rs. 410/- per equity share of Rs 10/- each for the year ended March 31, 2024, subject to approval of the Shareholders at the ensuing Eightieth Annual General Meeting of the Company scheduled to be held on August 8, 2024."

Abbott India Share Performance & Return: The 52-week high price of Abbott India share on BSE is Rs 29,628.15 per share (as on 16/02/2024) and 52-week low price is Rs 20,594.25 apiece (as on 19/05/2023). The company has a market capitalisation of Rs 54,306.95 crore. Abbott India shares fell 3.94% in last 1-week, declined over 8% in last 3-months, rallied 7% in last 6-months, and zoomed 17% in last 1-year. In last 2-years, Abbott India shares gained 53%. Abbott India shares surged 1346%.

About: Since 1910, Abbott has been dedicated to helping people in India live healthier lives through a diverse range of science-based nutritional products, diagnostic tools, branded generic pharmaceuticals, and diabetes and vascular devices. Headquartered in Mumbai, Abbott India Limited, a publicly listed company and a subsidiary of Abbott Laboratories, offers medicines in multiple therapeutic categories such as women's health, gastroenterology, cardiology, metabolic disorders and primary care, according to official website.

Disclaimer: The stock highlights the dividend, Q4 results and is not a recommendation to buy, sell or hold. We have not done fundamental or technical analysis and have no opinion on the stock mentioned. Neither, the author nor Greynium Information Technologies should be held liable for any losses. Please consult a professional advisor.